An observational study in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Bristol-Myers Squibb. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 1 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.
Among the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 2nd largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2026, is one of 15 observational ones, reaches primary completion later than 8 of the 13 other live ones, and was the 31st registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →9 of the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in China
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom
Ages 18+
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 6 · Phase 4 2
First in 2014; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 800 is above the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 55 across the 16 interventional studies, 200 across the 15 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,560 studies on the registry; 117 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
6 of the studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06146660Bristol-Myers SquibbA Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | 2026-11-30 |
| NCT07557498Bristol-Myers SquibbMavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US | 2026-12-14 |
| NCT07541833Bristol-Myers SquibbEffectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) | 2026-12-31 |
| NCT06551129Bristol-Myers SquibbReal-world Patient Reported Outcomes Among Patients Treated With Camzyos | 2026-12-31 |
| NCT07846059Bristol-Myers SquibbEvaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will describe how mavacamten is used in routine care for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), including use as monotherapy or with other background/concomitant oHCM medications.
The study will include adults in China diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) who initiated mavacamten treatment between 24 October 2024 and 31 March 2026.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following criteria to be included:
Exclusion Criteria:
Participants meeting any of the following criteria will be excluded:
(1) Prior Use of Study Drug: Have any documented history of Mavacamten use (based on medical history records, prescription records, or clinical notes) at any time prior to the Index Date.
Participants who initiate mavacamten as monotherapy and remained on monotherapy throughout follow-up.
Drug: Mavacamten
Participants who initiate mavacamten monotherapy and subsequently added one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications during follow-up.
Drug: Mavacamten
Participants who initiate mavacamten with one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications and remain on combination therapy throughout follow-up.
Drug: Mavacamten
Participants who initiate mavacamten with one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications and subsequently discontinued all background oHCM medications, resulting in mavacamten monotherapy.
Drug: Mavacamten
Participants whose treatment records indicate multiple treatment changes that could not be classified into the predefined treatment strategy groups.
Drug: Mavacamten
As per product label
Number of participants in each study cohort
Time frame: Baseline and months 1, 2, 3, 6, 9, 12 and 15
Absolute change (mmHg) from baseline in resting peak left ventricular outflow tract (LVOT) gradient assessed by transthoracic echocardiography
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
Absolute change (mmHg) from baseline in post-Valsalva peak left ventricular outflow tract (LVOT) gradient assessed by transthoracic echocardiography
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
Number of participants with at least 1-class improvement from baseline in New York Heart Association (NYHA) functional class
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
New York Heart Association (NYHA) functional class classification as assessed by the treating physician
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
Change from baseline in left atrial dimension (LAD) or left atrial volume index (LAVI) assessed by transthoracic echocardiography
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
Change from baseline in interventricular septal thickness (IVST) assessed by transthoracic echocardiography
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
Change from baseline in E/e' ratio assessed by transthoracic echocardiography
Time frame: Baseline and months 1, 2, 3, 6, 9, 12 and 15
Prescribed mavacamten dose (mg)
Time frame: Day 1 and months 1, 2, 3, 6, 9, 12 and 15
Prescribed mavacamten maintenance dose (mg) during follow-up
Time frame: Up to 15 months
Number of participants reaching mavacamten maintenance dose
Time frame: Up to 15 months
Number of participants whose prescribed mavacamten dose changed during the observation period
Time frame: Day 1 and and up to 15 months
Time (days) from Index Date to achieving mavacamten maintenance dose
Time frame: Day 1 and up to 15 months
Number of participants that discontinued mavacamten treatment
Time frame: Up to 15 months
Time (days) from Index Date to mavacamten discontinuation
Time frame: Day 1 and up to 15 months
Duration of mavacamten treatment during follow-up
Time frame: Day 1 and up to 15 months
Prior hypertrophic cardiomyopathy (oHCM) medication drug class
Drug class of background oHCM medications, including beta-blockers and calcium channel blockers
Time frame: Baseline and up to 15 months
Prior hypertrophic cardiomyopathy (oHCM) medication dose
Dose of background oHCM medications, including beta-blockers and calcium channel blockers
Time frame: Baseline and up to 15 months
Plan to share: No
Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →